Abstract Details

Title Short-Term Efficacy and Safety of Preladenant, a Selective Adenosine[sub]2A[/sub] Receptor Antagonist, in Patients with Parkinson[apos]s Disease and Levodopa-Related Motor Complications

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 006

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Matthew D. Troyer, MD (Denali Therapeutics)	Dr. Troyer has received personal compensation for serving as an employee of Denali Therapeutics Inc. Dr. Troyer has stock in Denali Therapeutics Inc. Dr. Troyer has stock in Merck & Co., Inc. Dr. Troyer has stock in Eli Lilly.
Igor Grachev	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Panayiotis Mitsias, MD (Henry Ford Hospital, Neurology)	Dr. Mitsias has nothing to disclose.
	No disclosure on file
Tony W. Ho, MD (AstraZeneca)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��